抗 CD38 单克隆抗体 Daratumumab 抗原发性渗出性淋巴瘤的疗效与机制 Efficacy and mechanism of the anti-CD38 monoclonal antibody Daratumumab against primary effusion lymphoma. PubMed 2021/09/20 发表Cancer Immunol ImmunotherQ1 · IF 5.8(JCR 2025) 靶点:CD38技术:NK 细胞多发性骨髓瘤淋巴瘤地区:日本